Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021

• Published in: The Lancet global health Vol. 10; no. 12; pp. e1807 - e1814
• Main Authors: Mirzoev, Azamdzhon, Macklin, Grace R, Zhang, Yiting, Mainou, Bernardo A, Sadykova, Umeda, Olsavszky, Victor Stefan, Huseynov, Shahin, Ruziev, Murodali, Saidzoda, Faizali, Bobokhonova, Mahtob, Mach, Ondrej
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-12-2022
• Subjects: Antibodies, Viral; Child; Humans; Immunization Programs; Poliomyelitis - epidemiology; Poliomyelitis - prevention & control; Poliovirus; Poliovirus Vaccine, Oral; Seroepidemiologic Studies; Tajikistan - epidemiology; Tajikistan
• ISSN: 2214-109X; 2214-109X
• DOI: 10.1016/S2214-109X(22)00412-0

Novel oral poliovirus vaccine type 2 (nOPV2) was used to control an outbreak of type 2 circulating vaccine derived poliovirus (cVDPV2) in Tajikistan, in 2021. We measured seroconversion and seroprevalence of type 2 polio antibodies in children who were reported to have received two doses of nOPV2 in outbreak response campaigns.
In this community serosurvey, children born after Jan 1, 2016 were enrolled from seven districts in Tajikistan. Dried blood spot cards were collected before nOPV2 campaigns and after the first and second rounds of the campaigns and were sent to the Centers for Disease Control and Prevention (Atlanta, GA, USA) for microneutralisation assay to determine presence of polio antibodies. The primary endpoint was to assess change in seroprevalence and seroconversion against poliovirus serotype 2 after one and two doses of nOPV2.
228 (97%) of 236 enrolled children were included in the analysis. The type 2 antibody seroprevalence was 26% (53/204; 95% CI 20 to 33) before nOPV2, 77% (161/210; 70 to 82) after one dose of nOPV2, and 83% (174/209; 77 to 88) after two doses of nOPV2. The increase in seroprevalence was statistically significant between baseline and after one nOPV2 dose (51 percentage points [42 to 59], p<0·0001), but not between the first and second doses (6 percentage points [–2 to 15], p=0·12). Seroconversion from the first nOPV2 dose, 67% (89/132; 59 to 75), was significantly greater than that from the second nOPV2 dose, 44% (20/45; 30 to 60; χ2 p=0·010). Total seroconversion after two nOPV2 doses was 77% (101/132; 68 to 83).
Our study demonstrated strong immune responses following nOPV2 outbreak response campaigns in Tajikistan. Our results support previous clinical trial data on the generation of poliovirus type 2 immunity by nOPV2 and provide evidence that nOPV2 can be appropriate for the cVDPV2 outbreak response. The licensure and WHO prequalification of nOPV2 should be accelerated to facilitate wider use of the vaccine.
World Health Organization, Centers for Disease Control and Prevention, and Rotary International.